کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2103497 1546273 2014 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Effects of Priming with Recombinant Human Granulocyte Colony–Stimulating Factor on Conditioning Regimen for High-Risk Acute Myeloid Leukemia Patients Undergoing Human Leukocyte Antigen–Haploidentical Hematopoietic Stem Cell Transplantation: A Multicenter
ترجمه فارسی عنوان
اثرات پرایمر با فاکتور تحریک کننده گرانولوسیت انسانی بر رژیم های تهویه برای بیماران مبتلا به لوسمی حاد میوولید لوسمی مبتلا به لنفوسیت های انسانی انسداد مجاری پیوند سلول های بنیادی هماتوپوئیدی: چند مرکز
کلمات کلیدی
لوسمی میلوئید حاد ریسک بالا، متنفرم پیوند سلول بنیادی هماتوپوئیت، فاکتور تحریک کننده کلنی گرانولسیتیک، آغازگر
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی


• Granulocyte colony–stimulating factor priming HLA-haploidentical hematopoietic stem cell transplantation improved leukemia-free survival and overall survival of high-risk acute myeloid leukemia patients.
• Granulocyte colony–stimulating factor priming HLA-haploidentical hematopoietic stem cell transplantation didn't increase the incidence of graft-versus-host disease and infection.
• Patients with no M4/M5/M6 subtype will benefit from granulocyte colony–stimulating factor–priming HLA-haploidentical hematopoietic stem cell transplantation.

HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an effective and immediate treatment for high-risk acute myeloid leukemia (HR-AML) patients lacking matched donors. Relapse remains the leading cause of death for HR-AML patients after haplo-HSCT. Accordingly, the prevention of relapse remains a challenge in the treatment of HR-AML. In a multicenter randomized controlled trial in southwestern China, 178 HR-AML patients received haplo-HSCT with conditioning regimens involving recombinant human granulocyte colony–stimulating factor (rhG-CSF) or non–rhG-CSF. The cumulative incidences of relapse and graft-versus-host disease (GVHD), 2-year leukemia-free survival (LFS), and overall survival (OS) were evaluated. HR-AML patients who underwent the priming conditioning regimen with rhG-CSF had a lower relapse rate than those who were treated with non-rhG-CSF (38.2%; 95% confidence interval [CI], 28.1% to 48.3% versus 60.7%, 95% CI, 50.5% to 70.8%; P < .01). The cumulative incidences of acute GVHD, chronic GVHD, transplantation-related toxicity, and infectious complications appeared to be equivalent. In total, 53 patients in the rhG-CSF–priming group and 31 patients in the non-rhG-CSF–priming group were still alive at the median follow-up time of 42 months (range, 24 to 80 months). The 2-year probabilities of LFS and OS in the rhG-CSF–priming and non-rhG-CSF–priming groups were 55.1% (95% CI, 44.7% to 65.4%) versus 32.6% (95% CI, 22.8% to 42.3%) (P < .01) and 59.6% (95% CI, 49.4% to 69.7%) versus 34.8% (95% CI, 24.9% to 44.7%) (P < .01), respectively. Multivariate analyses indicated that the 2-year probability of LFS of patients who achieved complete remission (CR) before transplantation was better than that of patients who did not achieve CR. The 2-year probability of LFS of patients with no M4/M5/M6 subtype was better than that of patients with the M4/M5/M6 subtype in the G-CSF–priming group (67.4%; 95% CI, 53.8% to 80.9% versus 41.9%; 95% CI, 27.1% to 56.6%; P < .05). This study suggests that the rhG-CSF–priming conditioning regimen is an acceptable choice for HR-AML patients, especially for the patients with no M4/M5/M6 subtype who achieved CR before transplantation.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: - Volume 20, Issue 12, December 2014, Pages 1932–1939
نویسندگان
, , , , , , , , , , , , , , , , , , , , ,